The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Local oestrogen for vaginal atrophy in postmenopausal women
Open accessAbstract
BACKGROUND: Vaginal atrophy is a frequent complaint of postmenopausal women; symptoms include vaginal dryness, itching, discomfort and painful intercourse. Systemic treatment for these symptoms in the form of oral hormone replacement therapy is not always necessary. An alternative choice is oestrogenic preparations administered vaginally (in the form of creams, pessaries, tablets and the oestradiol-releasing ring). This is an update of a Chochrane systematic review; the original version was first published in October 2006. OBJECTIVES: The objective of this review was to compare the efficacy and safety of intra-vaginal oestrogenic preparations in relieving the symptoms of vaginal atrophy in postmenopausal women. SEARCH METHODS: We searched the following databases and trials registers to April 2016: Cochrane Gynaecology and Fertility Group Register of trials, The Cochrane Central Register of Controlled Trials (CENTRAL; 2016 issue 4), MEDLINE, Embase, PsycINFO, DARE, the Web of Knowledge, OpenGrey, LILACS, PubMed and reference lists of articles. We also contacted experts and researchers in the field. SELECTION CRITERIA: The inclusion criteria were randomised comparisons of oestrogenic preparations administered intravaginally in postmenopausal women for at least 12 weeks for the treatment of symptoms resulting from vaginal atrophy or vaginitis. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial eligibility and risk of bias and extracted the data. The primary review outcomes were improvement in symptoms (participant-assessed), and the adverse event endometrial thickness. Secondary outcomes were improvement in symptoms (clinician-assessed), other adverse events (breast disorders e.g. breast pain, enlargement or engorgement, total adverse events, excluding breast disorders) and adherence to treatment. We combined data to calculate pooled risk ratios (RRs) (dichotomous outcomes) and mean differences (MDs) (continuous outcomes) and 95% confidence intervals (CIs). Statistical heterogeneity was assessed using the I(2) statistic. We assessed the overall quality of the evidence for the main comparisons using GRADE methods. MAIN RESULTS: We included 30 RCTs (6235 women) comparing different intra-vaginal oestrogenic preparations with each other and with placebo. The evidence was low to moderate quality; limitations were poor reporting of study methods and serious imprecision (effect estimates with wide confidence intervals)1. Oestrogen ring versus other regimensOther regimens included oestrogen cream, oestrogen tablets and placebo. There was no evidence of a difference in improvement in symptoms (participant assessment) either between oestrogen ring and oestrogen cream (odds ratio (OR) 1.33, 95% CI 0.80 to 2.19, two RCTs, n = 341, I(2) = 0%, low-quality evidence) or between oestrogen ring and oestrogen tablets (OR 0.78, 95% CI 0.53 to 1.15, three RCTs, n = 567, I(2) = 0%, low-quality evidence). However, a higher proportion of women reported improvement in symptoms following treatment with oestrogen ring compared with placebo (OR 12.67, 95% CI 3.23 to 49.66, one RCT, n = 67). With respect to endometrial thickness, a higher proportion of women who received oestrogen cream showed evidence of increase in endometrial thickness compared to those who were treated with oestrogen ring (OR 0.36, 95% CI 0.14 to 0.94, two RCTs, n = 273; I(2) = 0%, low-quality evidence). This may have been due to the higher doses of cream used. 2. Oestrogen tablets versus other regimensOther regimens in this comparison included oestrogen cream, and placebo. There was no evidence of a difference in the proportions of women who reported improvement in symptoms between oestrogen tablets and oestrogen cream (OR 1.06, 95% CI 0.55 to 2.01, two RCTs, n = 208, I(2) = 0% low-quality evidence). A higher proportion of women who were treated with oestrogen tablets reported improvement in symptoms compared to those who received placebo using a fixed-effect model (OR 12.47, 95% CI 9.81 to 15.84, two RCTs, n = 1638, I(2) = 83%, low-quality evidence); however, using a random-effect model did not demonstrate any evidence of a difference in the proportions of women who reported improvement between the two treatment groups (OR 5.80, 95% CI 0.88 to 38.29). There was no evidence of a difference in the proportions of women with increase in endometrial thickness between oestrogen tablets and oestrogen cream (OR 0.31, 95% CI 0.06 to 1.60, two RCTs, n = 151, I(2) = 0%, low-quality evidence).3. Oestrogen cream versus other regimensOther regimens identified in this comparison included isoflavone gel and placebo. There was no evidence of a difference in the proportions of women with improvement in symptoms between oestrogen cream and isoflavone gel (OR 2.08, 95% CI 0.08 to 53.76, one RCT, n = 50, low-quality evidence). However, there was evidence of a difference in the proportions of women with improvement in symptoms between oestrogen cream and placeb
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Practice Bulletin No. 141 Management of Menopausal Symptoms
(2014) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000441353.20693.78 · Cited by 434
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
(2008) · Cited by 3,790
Chapter 9: Analysing Data and Undertaking Meta-Analyses
Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (2008) · Cited by 2,782
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Chapter 10: Addressing reporting biases
Egger, M., & Moher, D. (2011) · Cited by 997
(2013) · Menopause · doi:10.1097/gme.0b013e3182a122c2 · Cited by 560
Oestrogen Therapy and the Menopausal Syndrome
CAMPBELL, S., & WHITEHEAD, M. (1977) · Clinics in Obstetrics and Gynaecology · doi:10.1016/s0306-3356(21)00374-5 · Cited by 539
Local oestrogen for vaginal atrophy in postmenopausal women
Suckling, J. A., Kennedy, R., Lethaby, A., & Roberts, H. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001500.pub2 · Cited by 359
Self-citationVaginal Estrogen for Genitourinary Syndrome of Menopause: A Systematic Review
Rahn, D. D., Carberry, C., Sanses, T. V., Mamik, M. M., Ward, R. M., Meriwether, K. V., Olivera, C. K., Abed, H., Balk, E. M., & Murphy, M. (2014) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000526 · Cited by 309
Prevalence of Genitourinary Symptoms in the Late Menopause
Iosif, C. S., & Bekassy, Z. (1984) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.3109/00016348409155509 · Cited by 304
Bygdeman, M., & Swahn, M. L. (1996) · Maturitas · doi:10.1016/0378-5122(95)00955-8 · Cited by 299
Menopause Management — Getting Clinical Care Back on Track
Manson, J. E., & Kaunitz, A. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1514242 · Cited by 232
Comparative study: Replens versus local estrogen in menopausal women
Nachtigall, L. E. (1994) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56474-7 · Cited by 229
Vaginal pH as a marker for bacterial pathogens and menopausal status
Caillouette, J. C., Sharp, C. F., Zimmerman, G. J., & Roy, S. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70345-4 · Cited by 189
Rioux, J. E., Devlin, M. C., Gelfand, M. M., Steinberg, W. M., & Hepburn, D. S. (2018) · Menopause · doi:10.1097/gme.0000000000001220 · Cited by 168
Rioux, J. E., Devlin, C. M., Gelfand, M. M., Steinberg, W. M., & Hepburn, D. S. (2000) · Menopause · doi:10.1097/00042192-200007030-00005 · Cited by 167
Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet
Weisberg, E., Ayton, R., Darling, G., Farrell, E., Murkies, A., O'Neill, S., Kirkegard, Y., & Fraser, I. (2005) · Climacteric · doi:10.1080/13697130500087016 · Cited by 159
The vaginal epithelium in the postmenopause — cytology, histology and pH as methods of assessment
Nilsson, K., Risberg, B., & Heimer, G. (1995) · Maturitas · doi:10.1016/0378-5122(94)00863-3 · Cited by 159
The Detection and Management of Vaginal Atrophy
Johnston, S. L., Farrell, S. A., Bouchard, C., Farrell, S. A., Beckerson, L.-A., Comeau, M., Johnston, S. L., Lefebvre, G., & Παπαϊωάννου, Α. (2004) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)30662-4 · Cited by 154
Effective Treatment of Vaginal Atrophy With an Ultra–Low-Dose Estradiol Vaginal Tablet
Simon, J. A., Nachtigall, L. E., Gut, R., Lang, E., Archer, D. F., & Utian, W. H. (2008) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31818aa7c3 · Cited by 154
Long, C., Liu, C., Hsu, S., Wu, C., Wang, C.-L., & Tsai, E. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000227401.98933.0b · Cited by 145
Efficacy of Low-Dose Estradiol Vaginal Tablets in the Treatment of Atrophic Vaginitis
Bachmann, G. A., Løbo, R. A., Gut, R., Nachtigall, L. E., & Notelovitz, M. (2008) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000296714.12226.0f · Cited by 145
Henriksson, L., Stjernquist, M., Boquist, L., et al. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70378-2 · Cited by 145
Local estrogen treatment in patients with urogenital symptoms
Šimunić, V., Banović, I., Ciglar, S., Jeren, L., Baldani, D. P., & Šprem, M. (2003) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(03)00200-5 · Cited by 144
Eriksen, P. S., & Rasmussen, H. (1992) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0028-2243(92)90059-8 · Cited by 139
Ayton, R. A., Darting, G. M., Murkies, A. L., Farrell, E. A., Weisberg, E., Selinus, I., & Fraser, I. S. (1996) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1996.tb09741.x · Cited by 139
Nilsson, K., & Heimer, G. M. (1992) · Maturitas · doi:10.1016/0378-5122(92)90246-z · Cited by 131
Barentsen, R., van de Weijer, P. H. M., & Schram, J. H. N. (1997) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(96)02612-7 · Cited by 127
Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally
Bachmann, G. A., Bouchard, C., Hoppe, D., Ranganath, R., Altomare, C. J., Vieweg, A. J., Graepel, J., & Helzner, E. C. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181a48c4e · Cited by 124
Climacteric symptoms among women aged 60–62 in Linköping, Sweden, in 1986
Berg, G. E., Gottqall, T., Hammar, M. L., & Lindgren, R. (1988) · Maturitas · doi:10.1016/0378-5122(88)90022-9 · Cited by 123
Managing the menopause: An update
Roberts, H., & Hickey, M. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.01.007 · Cited by 121
Self-citationEfficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women
Dessole, S., Rubattu, G., Ambrosini, G., Gallo, Ó. A. M., Capobianco, G., Cherchi, P. L., Marci, R., & Cosmi, E. (2004) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000077620.13164.62 · Cited by 106
Lose, G., & Englev, E. (2000) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2000.tb10408.x · Cited by 104
Raghunandan, C., Agrawal, S., Dubey, P., Choudhury, M., & Jain, A. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01667.x · Cited by 90
Fernandes, T., Costa‐Paiva, L., & Pinto-Neto, A. M. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12473 · Cited by 90
Henriksson, L., Stjernquist, M., Boquist, L., Ålander, U., & Selinus, I. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(94)90074-4 · Cited by 87
Casper, F., & Petri, E. (1999) · International Urogynecology Journal · doi:10.1007/s001920050040 · Cited by 87
Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets
Mettler, L., & Olsen, P. G. (1991) · Maturitas · doi:10.1016/0378-5122(91)90144-f · Cited by 85
Clarifying the Ethics of Clinical Research: A Path toward Avoiding the Therapeutic Misconception
Appelbaum, P. S. (2002) · The American Journal of Bioethics · doi:10.1162/152651602317533596 · Cited by 85
Clinical trial of the estradiol vaginal ring in the U.S.
Nachtigall, L. E. (1995) · Maturitas · doi:10.1016/0378-5122(95)00963-9 · Cited by 84
DUGAL, R., HESLA, K., Sørdal, T., AASE, K. H., LILLEEIDET, O., & Wickström, E. (2000) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1034/j.1600-0412.2000.079004293.x · Cited by 82
Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms
Speroff, L. (2003) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(03)00764-6 · Cited by 77
Cano, A., Estévez, J., Usandizaga, R., Gallo, J. L. R., Guinot, M., Delgado⋈, J. L., Castellanos, E., Moral, E., Nieto, C., del Prado, J. M., et al. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3182518e9a · Cited by 76
Local oestrogen for vaginal atrophy in postmenopausal women
Suckling, J. A., Lethaby, A. E., & Kennedy, R. (2003) · doi:10.1002/14651858.cd001500 · Cited by 74
Self-citationKicovic, P. M., Cortés-Prieto, J., Milojević, S., Haspels, A. A., & Aljinovic, A. (1980) · Maturitas · doi:10.1016/0378-5122(80)90029-8 · Cited by 71
Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy
Jaisamrarn, U., Triratanachat, S., Chaikittisilpa, S., Grob, P., Prasauskas, V., & Taechakraichana, N. (2013) · Climacteric · doi:10.3109/13697137.2013.769097 · Cited by 68
Compston, J. E. (1992) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a072549 · Cited by 68
Vaginal Estrogen Preparations: A Review of Safety and Efficacy for Vaginal Atrophy
Crandall, C. J. (2002) · Journal of Women s Health · doi:10.1089/154099902762203704 · Cited by 65
Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy
Holmgren, P.-Å., Lindskog, M., & von Schoultz, B. (1989) · Maturitas · doi:10.1016/0378-5122(89)90120-5 · Cited by 63
Griesser, H., Skonietzki, S., Fischer, T. H., Fielder, K., & Suesskind, M. (2012) · Maturitas · doi:10.1016/j.maturitas.2011.12.022 · Cited by 63
Manonai, J., Theppisai, U., Suthutvoravut, S., Udomsubpayakul, U., & Chittacharoen, A. (2001) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2001.tb01266.x · Cited by 63
Effective treatment of vaginal atrophy with isoflavone vaginal gel
Lima, S. M. R. R., Yamada, S. S., Reis, B. F., Postigo, S., da Silva, M. A. L. G., & Aoki, T. (2013) · Maturitas · doi:10.1016/j.maturitas.2012.11.012 · Cited by 61
Vaginal administration of low-dose oestradiol — effects on the endometrium and vaginal cytology
Mattsson, L. ‐., Cullberg, G., Eriksson, O., & Knutsson, F. (1989) · Maturitas · doi:10.1016/0378-5122(89)90213-2 · Cited by 55
Foidart, J. M., Vervliet, J., & Buytaert, P. (1991) · Maturitas · doi:10.1016/0378-5122(91)90092-5 · Cited by 53
Karp, D. R., Jean‐Michel, M., Johnston, Y., Suciu, G., Aguilar, V. C., & Davila, G. W. (2012) · Urogynecology · doi:10.1097/spv.0b013e31825e6401 · Cited by 49
Reviewing the options for local estrogen treatment of vaginal atrophy
Lindahl, S. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s52555 · Cited by 49
Cicinelli, E., Naro, E. D., de Ziegler, D., Matteo, M., Morgese, S., Galantino, P., Brioschi, P.-A., & Schönauer, S. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.341 · Cited by 47
Review of the endometrial safety during intravaginal treatment with estriol
Vooijs, G. P., & Geurts, T. B. P. (1995) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0301-2115(95)02170-c · Cited by 47
Urogenital aging: solutions in clinical practice
Notelovitz, M. (1997) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(97)90197-1 · Cited by 45
Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis
Marx, P., Schade, G., Wilbourn, S., Blank, S., Moyer, D. L., & Nett, R. (2003) · Maturitas · doi:10.1016/s0378-5122(03)00240-8 · Cited by 42
Vartiainen, J., Wahlström, T., & Nilsson, C.-G. (1993) · Maturitas · doi:10.1016/0378-5122(93)90008-6 · Cited by 34
The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status
Gupta, P., Özel, B. Z., Stanczyk, F. Z., Felix, J. C., & Mishell, D. R. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318148b98b · Cited by 33
Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa
Wolff, J. P., Cachelou, R., & Guéritée, N. (1982) · Maturitas · doi:10.1016/0378-5122(82)90054-8 · Cited by 32
Histologic and Cytologic Effects of Vaginal Estrogen in Women With Pelvic Organ Prolapse
Vaccaro, C. M., Mutema, G. K., Fellner, A. N., Crisp, C. C., Estanol, M. V., Kleeman, S. D., & Pauls, R. N. (2013) · Urogynecology · doi:10.1097/spv.0b013e318278cc40 · Cited by 32
Raymundo, N. T., Yu-cheng, B., Zi-yan, H., Lai, C. H., Leung, K., Subramaniam, R., Bin-rong, C., Ling, Y., Nasri, N. W. M., & Calimon, N. (2004) · Climacteric · doi:10.1080/13697130400003147 · Cited by 30
Akrivis, C., Varras, M., Thodos, A., Hadjopoulos, G., Bellou, A., & Antoniou, N. (2003) · PubMed · Cited by 14
Bazin, S., Lefebvre, J., Fortier, M. P., Brisson, J., Brouillette, F., Bujold, E., & Bouchard, C. (2011) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)34987-8 · Cited by 14
Rao, A., Steels, E., Vitetta, L., Inder, W. J., & Beccaria, G. (2014) · Menopause The Journal of The North American Menopause Society · Cited by 1
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
ESHRE Guideline: management of women with premature ovarian insufficiency
(2016) · Human Reproduction · doi:10.1093/humrep/dew027 · Cited by 1,555
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Metadata
- Authors
- Lethaby, A., Ayeleke, R. O., & Roberts, H.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-08-31
- Volume
- 2016
- Issue
- 11
- Pages
- CD001500-CD001500
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1662696737
- Cited by
- 601
- References
- 72
- FWCI
- 46.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.